Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | EEF2K | O00418 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139911 | 0.86 | CA12 (0.41) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL4563033 | 0.85 | CA12 (0.43) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL3153636 | 0.84 | MAPK1 (0.39) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL28775410 | 0.84 | LMNA (0.43) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL4380379 | 0.84 | TSHR (0.43) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL29667787 | 0.81 | CA2 (0.51) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL8730036 | 0.80 | AOX1 (0.45) | CA12CA1CA2CA9POLB | |
| SCHEMBL8732810 | 0.80 | MAPT (0.41) | L3MBTL1SMN1; SMN2ALDH1A1TDP1MEN1 | |
| SCHEMBL196945 | 0.79 | ALDH1A1 (0.48) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL3009714 | 0.79 | CA12 (0.41) | CA12CA1CA2CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-10385097-B2 | Ether compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2017035411-A1 | ETHER COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-2522394-B1 | Substituted phosphonates and their use decreasing amyloid aggregates | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-8513219-B2 | Substituted phosphonates and their use in decreasing amyloid aggregates | QUEEN MARY & WESTFIELD COLLEGE, UNIVERSITY OF LONDON (GB) | 2013-08-20 | — | — | US | disclosed |
| EP-2522394-A2 | Substituted phosphonates and their use decreasing amyloid aggregates | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2012-11-14 | — | — | EP | disclosed |
| EP-2424541-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | Limerick BioPharma, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20070049761-A1 | Substituted phosphonate fluorescent sensors and use thereof | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2007-03-01 | — | — | US | disclosed |
| EP-1625134-A2 | SUBSTITUTED PHOSPHONATE FLUORESCENT SENSORS AND USE THEREOF | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101579-A2 | SUBSTITUTED PHOSPHONATE FLUORESCENT SENSORS AND USE THEREOF | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2004-11-25 | — | — | WO | disclosed |
| EP-0723969-B1 | Phosphonocarboxylic acid derivatives and their use in treating degenerative articular ailments | HOECHST AG (DE) | 2001-11-14 | — | — | EP | disclosed |
| US-5726165-A | HYPOGLYCEMIC AGENTS; DIETETICS; GASTROINTESTINAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-03-10 | — | — | US | disclosed |
| EP-0772585-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1997-05-14 | — | — | EP | disclosed |
| US-5627173-A | Phosphonoacetic acid derivatives and their use for treating degenerative joint disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-06 | — | — | US | disclosed |
| EP-0723969-A1 | Phosphonocarboxylic acid derivatives and their use in treating degenerative articular ailments | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996004234-A1 | ARYLOXY ANDARYCTHIO PROPANOLAMINE DERIVATIVES USEFUL AS B3-ADRENORECEPTOR AGONISTS AND ANTAGONS OF THE B1 AND B2 ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996004233-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385097-B2 | Ether compounds for treatment of medical disorders | CFD, TFPI, F12 | CA12 3631/4885CA1 4805/4885CA2 4025/4885 |
| US-20070049761-A1 | Substituted phosphonate fluorescent sensors and use thereof | NR2E3, CASR, NR3C2 | CA12 1254/4885CA1 578/4885CA2 111/4885 |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | PC, PCK1, PYGL | CA12 4290/4885CA1 2781/4885CA2 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.